Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz

HIV Med. 2002 Oct;3(4):287-9. doi: 10.1046/j.1468-1293.2002.00126.x.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkynes
  • Benzoxazines
  • Blood Glucose / drug effects
  • Cholesterol / blood*
  • Cyclopropanes
  • Drug Therapy, Combination
  • Follow-Up Studies
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / blood
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Oxazines / blood
  • Oxazines / therapeutic use
  • Reverse Transcriptase Inhibitors / blood
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Ritonavir / blood
  • Ritonavir / therapeutic use
  • Saquinavir / blood
  • Saquinavir / therapeutic use
  • Triglycerides / blood*

Substances

  • Alkynes
  • Benzoxazines
  • Blood Glucose
  • Cyclopropanes
  • HIV Protease Inhibitors
  • Oxazines
  • Reverse Transcriptase Inhibitors
  • Triglycerides
  • Cholesterol
  • efavirenz
  • Saquinavir
  • Ritonavir